COMMUNIQUÉS West-GlobeNewswire

Nuvaira Announces Enrollment Completion in First Sham-Controlled Clinical Trial of Targeted Lung Denervation for COPD
27/06/2017
MINNEAPOLIS, June 27, 2017 (GLOBE NEWSWIRE) -- Nuvaira (formerly known as Holaira), a developer of medical devices to treat obstructive lung diseases, today announced completion of patient enrollment in the AIRFLOW-2 [...]
Nuvaira annonce l'achèvement de l'inscription pour le premier essai clinique à groupe témoin fictif contre la dénervation pulmonaire ciblée pour la MPOC
27/06/2017
MINNEAPOLIS, le 27 juin 2017 (GLOBE NEWSWIRE) - Nuvaira (anciennement connue sous le nom de Holaira), développeur de dispositifs médicaux pour traiter les maladies pulmonaires obstructives, a annoncé aujourd'hui l' [...]
Bavarian Nordic Announces Positive Data from Ongoing Phase 2 Study Investigating a Universal RSV Vaccine
27/06/2017
Company to host conference call at 3 pm CEST (9 am EDT) today to review study results First RSV vaccine to show immunogenicity against five distinct RSV proteins 421 subject study shows vaccine was well tolerated at all [...]
Arix Bioscience participates in $20 million fundraise for Mitoconix Bio
27/06/2017
Arix Bioscience participates in $20 million fundraise for Mitoconix Bio Series A finance raised by high quality investor syndicate for neurodegenerative diseases therapies LONDON, 27 June, 2017: Arix Bioscience plc (LSE [...]
Affimed Presents Preclinical Data on AFM24 and AFM26 at EACR-AACR-SIC 2017
27/06/2017
Heidelberg, Germany, June 27, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today the presentation [...]
Demand for Cosmetic Surgery Procedures Around the World Continues to Skyrocket - USA, Brazil, Japan, Italy and Mexico Ranked in the Top Five Countries
27/06/2017
NEW YORK, June 27, 2017 (GLOBE NEWSWIRE) -- The International Society of Aesthetic Plastic Surgery (ISAPS) today released the results of their annual Global Aesthetic Survey for procedures completed in 2016, which [...]
Nexstim Plc Files 510(k) Submission for its NBT® system for the Treatment of Depression with US FDA
27/06/2017
Company announcement, Helsinki, 27 June 2017 at 9 am Nexstim Plc Files 510(k) Submission for its NBT® system for the Treatment of Depression with US FDA Nexstim Plc (NXTMH:HEX, NXTMS:STO) (" Nexstim " or " Company "), a [...]
Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across Europe
27/06/2017
Dose escalation trial will evaluate RPL554 as a maintenance treatment in approximately 400 COPD patients LONDON, June 27, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical- [...]
Sanofi and Regeneron Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union
27/06/2017
Sanofi and Regeneron Announce Approval of Kevzara ® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union Paris, France and Tarrytown, N.Y., June 27, 2017 - [...]
Sanofi et Regeneron annoncent l'approbation de Kevzara® (sarilumab) dans l'Union européenne pour le traitement de la polyarthrite rhumatoïde active, modérée à sévère, de l'adulte
27/06/2017
Sanofi et Regeneron annoncent l'approbation de Kevzara ® (sarilumab) dans l'Union européenne pour le traitement de la polyarthrite rhumatoïde active, modérée à sévère, de l'adulte Paris (France) et Tarrytown (New York [...]
ABLYNX ACHIEVES SECOND MILESTONE IN IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO., INC., KENILWORTH, NEW JERSEY, USA
27/06/2017
GHENT, Belgium, 27 June 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that Merck & Co., Inc., Kenilworth, New Jersey, USA, known as MSD outside the United States and Canada, has started an IND- [...]
Ossur Hf : Transactions in relation to share buyback program
26/06/2017
Announcement from Össur hf. No. 46/2017 Reykjavík, 26 June 2017 On 1 December 2016, Össur hf. initiated a new share buy-back program, see Company announcement no. 96/2016. The purpose of the share buyback program is to [...]
Sanofi : Disclosure of trading in own shares
26/06/2017
Reporting EN This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]
Sanofi : Déclaration des transactions sur actions propres
26/06/2017
Reporting FR This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the [...]
Scientific breakthrough on objective diagnosis of PTSD
26/06/2017
Scientific breakthrough for non-invasive, automatic, objective diagnosis of PTSD leveraging autonomic biomarkers Accuracy of 80% (+/- 1%) for objectively diagnosing subjects with PTSD Medibio has exclusive worldwide [...]
Medtronic Announces Outcomes-Based Agreement with Aetna for Type 1 and Type 2 Diabetes Patients
26/06/2017
DUBLIN - June 26, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced a new outcomes-based agreement with Aetna (NYSE:AET) for type 1 and type 2 diabetes patients currently on [...]
Novo Nordisk A/S - Share repurchase programme
26/06/2017
Bagsværd, Denmark, 26 June 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Targovax ASA: Registration of capital increase following exercise of employee options and settlement of restricted stock units
26/06/2017
Reference is made to the stock exchange notice of 14 June 2017 regarding the board of directors' resolution to increase the share capital in Targovax ASA (the "Company") in connection with the exercise of employee [...]
Mithra Pharmaceuticals: ESTELLE® PHASE IIB RESULTS ON WELL-BEING AND BODY WEIGHT PUBLISHED IN LEADING PEER-REVIEWED JOURNAL
26/06/2017
PRESS RELEASE Estelle® Phase IIb results on well-being and BODY weight published in LEADING peer-reviewed journal European Journal Of Contraception and Reproductive Health Care publishes article on Phase IIb results of [...]

Pages